Ivy RX review

A broad catalogue still needs a narrow purpose

Ivy RX lists weight treatment, NAD+, sermorelin and other products. That can make services easier to find, but it does not show that several belong in the same person’s care. Begin with the actual clinical concern and the additional review or treatment being purchased. ^[7]

The service describes online assessment, clinical review and prescription fulfillment if approved. Its terms distinguish the platform’s role from services requiring a medical license. Paying for an online pathway is not a replacement for a regular clinician or a reason to regard the whole catalogue as comprehensive preventive care. ^{[4] [7]}

Define the health outcome with the research on weight loss and physical function.

For a California clinic and online care alternative, compare our JumpstartMD review.

Keep each starting price attached to its product

The current GLP-1 product begins at $77, labeled four doses per month. NAD+ begins at $179 with use-dependent pricing. Sermorelin’s product page also begins at $179, while the catalogue card shows $175. These labels need a selected preparation, quantity, paid term and renewal before they become comparable treatment budgets. ^{[1] [2] [3] [7]}

The NAD+ FAQ includes provider review, injection supplies and priority shipping in its stated price. That describes a useful bundle, but it does not define the supply for every buyer or establish that a second product has the same inclusions. I would compare complete written offers rather than assemble a monthly total from the smallest catalogue numbers. ^[1]

Separate the actual product and service costs in the complete care-cost planner.

The proposed vial needs its own evidence

NAD+ and sermorelin are described as injection products with energy, recovery, body-composition or sleep claims. Those goals do not establish a predictable result from the actual compounded preparation. A hormone change or biological role is a different finding from improved function or a meaningful clinical benefit. ^{[1] [2]}

FDA does not approve compounded medicines or review their safety, effectiveness and quality before marketing. The seller’s testing labels and references to registered laboratories do not change that status. The assigned pharmacy, supplied formulation and product-specific evidence still matter. ^[8]

Quality claims and customer surveys answer different questions

Ivy lists potency, sterility, endotoxin and pH checks. These describe the seller’s quality-testing approach, not a clinical trial or batch documentation for every order. A passed marker on a page should not be read as a guarantee of the treatment’s benefit. ^{[1] [2] [3]}

Its GLP-1 weight-loss percentage comes from an internal customer survey. That is neither a controlled comparison nor evidence for the NAD+ or sermorelin products. A broader age-defying presentation cannot connect outcomes across different medicines simply because they share a storefront. ^{[3] [7]}

For a distinct testing purchase, use our testing-service comparison.

Contact and dispensing should fit the care needed

The product pages advertise same-day review, patient-platform access and delivery; messaging is described through the patient portal. Those features may be useful, but review speed is not guaranteed approval or immediate clinical attention. Identify how the provider will reassess the actual plan when needed. ^{[1] [2] [3]}

The general FAQ says main prescriptions use partner pharmacies rather than an unrestricted buyer-selected pharmacy. Local fulfillment of some separately paid side-effect medicines is a limited exception. It also describes the main service as self-pay, without public or private insurance acceptance. Those details change the access and cost comparison. ^[6]

Recurring billing needs a clear endpoint

The public terms describe one-month or three-month prepayment followed by monthly renewal, with cancellation needed before the existing period ends. Support cancellation appears alongside later portal-management wording. Obtain the selected next date and amount, and retain the cancellation confirmation rather than assume the initial term repeats indefinitely. ^[4]

Medication returns are not accepted. The final-sale FAQ and the terms’ fifteen-day dissatisfaction-refund-request provision should be read together: a timely request through the specified channel with complete transaction details is not a refund promise. Financial flexibility should be established before paying for a larger supply. ^{[4] [5] [6]}

Consider clinical continuity alongside the evidence after GLP-1 treatment stops.

Compare what the extra care would add

Ivím is a useful alternative when a shared but separately charged clinical membership might serve more than one defined need. Ivy’s catalogue should instead be evaluated through the specific product and service selected. Neither model is made worthwhile by the number of available medicines.

Choose the arrangement that adds useful review, follow-up or access at an acceptable complete cost. If existing care already meets the need, a new anti-aging menu is not by itself a reason to add another recurring purchase.

Compare the shared care-membership model in our Ivím review.

Understanding the cost

Current product page: GLP-1 from $77, labeled four doses/month; NAD+ and sermorelin from $179, use varies. Catalogue sermorelin shows $175, conflicting with its product page. Actual medicine, supplied amount, first paid term and renewal need a selected quote. Public terms describe one- or three-month prepayment followed by monthly renewal, not a universal invoice for every offer. ^{[1] [2] [3] [4] [7]}